• Regeneron

    Regeneron Pharmaceuticals, Inc. reported a net income of $99 million, in the first quarter of 2013, compared to $12 million in the same period last year.

    The company also announced revenues of $440 million for the quarter, up from $232 million in the first quarter of 2012.  Total revenues included Eylea U.S. sales of $314 million in the quarter, compared to $124 million in the first quarter of 2012. 

    "The first quarter of 2013 was a productive quarter where we delivered sustained revenue and earnings growth," said Leonard S. Schleifer, MD, PhD, president and CEO.  "Eylea sales in the U.S. continue to enjoy strong growth and we are raising our estimate of full year U.S. Eylea net sales to $1.25 to $1.325 billion in 2013.  The ex-U.S. launch of Eylea by our partner, Bayer HealthCare, is also going very well and resulted in a positive contribution to our earnings this quarter."